• 1
    DeAngelis LM. Brain tumors. N Engl J Med 2001; 344: 11423.
  • 2
    Kleihues P,Louis DN,Scheithauer BW,Rorke LB,Reifenberger G,Burger PC,Cavenee WK. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002; 61: 21525 discussion 26–9.
  • 3
    Stupp R,Mason WP,van den Bent MJ,Weller M,Fisher B,Taphoorn MJ,Belanger K,Brandes AA,Marosi C,Bogdahn U,Curschmann J,Janzer RC, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 98796.
  • 4
    Wong ET,Hess KR,Gleason MJ,Jaeckle KA,Kyritsis AP,Prados MD,Levin VA,Yung WK. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999; 17: 25728.
  • 5
    Li LH,Fraser TJ,Olin EJ,Bhuyan BK. Action of camptothecin on mammalian cells in culture. Cancer Res 1972; 32: 264350.
  • 6
    Gallo RC,Whang-Peng J,Adamson RH. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J Natl Cancer Inst 1971; 46: 78995.
  • 7
    Friedman HS,Petros WP,Friedman AH,Schaaf LJ,Kerby T,Lawyer J,Parry M,Houghton PJ,Lovell S,Rasheed K,Cloughsey T,Stewart ES, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 1999; 17: 151625.
  • 8
    Cloughesy TF,Filka E,Kuhn J,Nelson G,Kabbinavar F,Friedman H,Miller LL,Elfring GL. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer 2003; 97: 23816.
  • 9
    Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J Neurooncol 2002; 56: 1838.
  • 10
    Prados MD,Lamborn K,Yung WK,Jaeckle K,Robins HI,Mehta M,Fine HA,Wen PY,Cloughesy T,Chang S,Nicholas MK,Schiff D, et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American brain tumor consortium study. Neuro Oncol 2006; 8: 18993.
  • 11
    Vredenburgh JJ,Desjardins A,Herndon JE,II,Dowell JM,Reardon DA,Quinn JA,Rich JN,Sathornsumetee S,Gururangan S,Wagner M,Bigner DD,Friedman AH, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007; 13: 12539.
  • 12
    Vredenburgh JJ,Desjardins A,Herndon JE,II,Marcello J,Reardon DA,Quinn JA,Rich JN,Sathornsumetee S,Gururangan S,Sampson J,Wagner M,Bailey L, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25: 47229.
  • 13
    Gradishar WJ. Albumin-bound nanoparticle paclitaxel. Clin Adv Hematol Oncol 2005; 3: 3489.
  • 14
    Muggia FM. Liposomal encapsulated anthracyclines: new therapeutic horizons. Curr Oncol Rep 2001; 3: 15662.
  • 15
    Slatter JG,Schaaf LJ,Sams JP,Feenstra KL,Johnson MG,Bombardt PA,Cathcart KS,Verburg MT,Pearson LK,Compton LD,Miller LL,Baker DS, et al. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drug Metab Dispos 2000; 28: 42333.
  • 16
    Rothenberg ML,Kuhn JG,Burris HA,III,Nelson J,Eckardt JR,Tristan-Morales M,Hilsenbeck SG,Weiss GR,Smith LS,Rodriguez GI, et al. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993; 11: 2194204.
  • 17
    Koizumi F,Kitagawa M,Negishi T,Onda T,Matsumoto S,Hamaguchi T,Matsumura Y. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res 2006; 66: 1004856.
  • 18
    Sumitomo M,Koizumi F,Asano T,Horiguchi A,Ito K,Kakizoe T,Hayakawa M,Matsumura Y. Novel SN-38-incorporated polymeric micelle, NK012, strongly suppresses renal cancer progression. Cancer Res 2008; 68: 16315.
  • 19
    Nakajima TE,Yasunaga M,Kano Y,Koizumi F,Kato K,Hamaguchi T,Yamada Y,Shirao K,Shimada Y,Matsumura Y. Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil. Int J Cancer 2008; 122: 214853.
  • 20
    Saito Y,Yasunaga M,Kuroda J,Koga Y,Matsumura Y. Enhanced distribution of NK012, a polymeric micelle-encapsulated SN-38, and sustained release of SN-38 within tumors can beat a hypovascular tumor. Cancer Sci 2008; 99: 125864.
  • 21
    Kawato Y,Furuta T,Aonuma M,Yasuoka M,Yokokura T,Matsumoto K. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 1991; 28: 1928.
  • 22
    Matsumura Y,Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 638792.
  • 23
    Maeda H,Matsumura Y,Kato H. Purification and identification of [hydroxyprolyl3]bradykinin in ascitic fluid from a patient with gastric cancer. J Biol Chem 1988; 263: 160514.
  • 24
    Matsumura Y,Maruo K,Kimura M,Yamamoto T,Konno T,Maeda H. Kinin-generating cascade in advanced cancer patients and in vitro study. Jpn J Cancer Res 1991; 82: 73241.
  • 25
    Dvorak HF,Nagy JA,Dvorak JT,Dvorak AM. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988; 133: 95109.
  • 26
    Leung DW,Cachianes G,Kuang WJ,Goeddel DV,Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 13069.
  • 27
    Abe K,Shoji M,Chen J,Bierhaus A,Danave I,Micko C,Casper K,Dillehay DL,Nawroth PP,Rickles FR. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA 1999; 96: 86638.
  • 28
    Belting M,Dorrell MI,Sandgren S,Aguilar E,Ahamed J,Dorfleutner A,Carmeliet P,Mueller BM,Friedlander M,Ruf W. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 2004; 10: 5029.
  • 29
    Rong Y,Post DE,Pieper RO,Durden DL,Van Meir EG,Brat DJ. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 2005; 65: 140613.
  • 30
    Hamada K,Kuratsu J,Saitoh Y,Takeshima H,Nishi T,Ushio Y. Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer 1996; 77: 187783.
  • 31
    Takano S,Yoshii Y,Kondo S,Suzuki H,Maruno T,Shirai S,Nose T. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 1996; 56: 218590.
  • 32
    Chowdhary S,Wong ET. Bevacizumab combined with irinotecan for recurrent glioblastoma multiforme–improvement over available therapy? Nat Clin Pract Neurol 2008; 4: 2423.
  • 33
    Chamberlain MC Bevacizumab plus irinotecan in recurrent glioblastoma. J Clin Oncol 2008; 26: 10123.
  • 34
    Plate KH,Breier G,Weich HA,Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992; 359: 8458.
  • 35
    Horten BC,Basler GA,Shapiro WR. Xenograft of human malignant glial tumors into brains of nude mice. A histopatholgical study. J Neuropathol Exp Neurol 1981; 40: 493511.
  • 36
    Giannini C,Sarkaria JN,Saito A,Uhm JH,Galanis E,Carlson BL,Schroeder MA,James CD. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol 2005; 7: 16476.
  • 37
    Engebraaten O,Hjortland GO,Hirschberg H,Fodstad O. Growth of precultured human glioma specimens in nude rat brain. J Neurosurg 1999; 90: 12532.
  • 38
    Galli R,Binda E,Orfanelli U,Cipelletti B,Gritti A,De Vitis S,Fiocco R,Foroni C,Dimeco F,Vescovi A. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004; 64: 701121.
  • 39
    Gunther HS,Schmidt NO,Phillips HS,Kemming D,Kharbanda S,Soriano R,Modrusan Z,Meissner H,Westphal M,Lamszus K. Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 2008; 27: 2897909.
  • 40
    Onda T,Nakamura I,Seno C,Matsumoto S,Kitagawa M,Okamoto K,Nishikawa K,Suzuki M. Superior antitumor activity of NK012, 7-etyhl-10-hydroxycamptothecin-incorporating micellar nanoparticle, to irinotecan [abstruct 3062]. Proc Am Assoc Cancer Res 2006; 47: 720s.
  • 41
    Kato K,Hamaguchi T,Shirao K,Shimada Y,Doi T,Ohtsu A,Matsumura Y,Yamada Y. Interim analysis of phase I study of NK012, polymer micelle SN-38, in patients with advanced cancer. Proc Am Soc Clin Oncol GI 2008 (Abstract no 485).
  • 42
    Burris HA,III,Infante JR,Spigel DR,Greco FA,Thompson DS,Matsumoto S,Kawamura S,Jones SF. A phase I dose-escalation study of NK012. Proc Am Soc Clin Oncol 2008 (Abstract no 2538).